Clinical Outcomes in Pediatric Obsessive-Compulsive Disorder

Status Recruiting

Clinical Trial Summary

Obsessive-Compulsive Disorder (OCD) is a common neuropsychiatric illness beginning in childhood. Effective OCD treatments include cognitive-behaviour therapy (CBT) and medications but access to treatment is difficult and does not systematically include parents. The investigators will evaluate clinical and neural effects of Group-based Family CBT (GF-CBT), via a case-control study including: Group 1 - OCD cases receiving GF-CBT (N=90); Group 2 - OCD waitlist cases (N=90). Effects will be measured between baseline and completion of 12 GF-CBT sessions: comparing OCD severity and functioning changes between Groups 1 and 2.

Clinical Trial Description

Effective OCD treatment approaches in children and youth include cognitive-behaviour therapy (CBT) and serotonergic medications; however, the disorder is under-diagnosed and access to care is frequently delayed or difficult to obtain. Moreover, despite the important role of family accommodation as an outcome predictor, standard CBT does not systematically include parents and mechanisms of response are not fully understood. The investigators propose to address this challenge by evaluating a novel treatment approach called Group-based Family CBT (GF-CBT). To determine clinical and neural effects of GF-CBT, we will perform a case-control study of two groups: Group 1 - OCD-affected youth receiving GF-CBT treatment (N=90); Group 2 - OCD-affected youth receiving no new treatment (waitlist controls; N=90). The investigators will collect clinical outcome data related to OCD severity, individual and family functioning at four time points for Group 1 subjects and at two time points for Group 2 subjects. For Group 1 subjects, these time points include baseline, at midpoint, at the completion of 12 sessions, and at one-month follow-up (all time points are +/- one week). For Group 2 subjects, time points will be at baseline and after a time delay equivalent to completion of 12 GF-CBT sessions. Clinical measures will be used to compare changes between GF-CBT treatment and waitlist-control groups (Groups 1 versus 2). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01635569
Study type	Interventional
Source	University of British Columbia
Contact	Diana Franco Yamin, MA
Email	dfrancoy@bcchr.ca
Status	Recruiting
Phase	N/A
Start date	October 1, 2012
Completion date	June 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04934007` - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder	N/A
Recruiting	`NCT04071990` - Family Involvement in CBGT of OCD: a Randomized Controlled Trial	N/A
Completed	`NCT02541968` - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Recruiting	`NCT05391503` - Light Therapy for Obsessive-compulsive Disorder (OCD)	N/A
Recruiting	`NCT04539951` - Pragmatic Trial of Obsessive-compulsive Disorder	Phase 2
Completed	`NCT03416504` - Methods for Managing Intrusive Thoughts	N/A
Not yet recruiting	`NCT06029738` - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD	N/A
Recruiting	`NCT02844049` - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS	N/A
Terminated	`NCT02909660` - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder	N/A
Completed	`NCT02911324` - Cannabinoid Medication for Adults With OCD	Phase 1/Phase 2
Completed	`NCT02217995` - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients	N/A
Terminated	`NCT02234011` - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder	Phase 2
Withdrawn	`NCT01953042` - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders	N/A
Completed	`NCT02655926` - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder	N/A
Completed	`NCT04919785` - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder	N/A
Terminated	`NCT00758966` - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder	Phase 2
Completed	`NCT00742664` - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project	Phase 1/Phase 2
Completed	`NCT00523718` - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder	Phase 2
Completed	`NCT00074815` - Treatment of Obsessive Compulsive Disorder in Children	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.